Wang Qingya, Huang Yuyin, Meng Kun, Zhang Haiou, Han Yunsheng, Zhang Rui, Han Xiling, Liu Guohua, Cai Hongying, Yang Peilong
Key Laboratory of Feed Biotechnology of Ministry of Agriculture and Rural Affairs, Institute of Feed Research, Chinese Academy of Agricultural Sciences, Beijing 100081, China.
Key Laboratory of Yunnan for Biomass Energy and Biotechnology of Environment, Yunnan Normal University, Kunming 650500, China.
Nutrients. 2025 Jul 17;17(14):2346. doi: 10.3390/nu17142346.
: Obesity is increasingly recognized as a global health concern due to its association with metabolic disorders and gut microbiota dysbiosis. While probiotics offer promise in regulating gut microbiota and improving host metabolism, strain-specific effects remain underexplored, particularly for canine-derived probiotics. This study aimed to isolate and characterize a novel probiotic strain, LA-1, and evaluate its anti-obesity effects and underlying mechanisms using a high-fat diet (HFD)-induced obese mouse model. : LA-1 was isolated from the feces of a healthy dog and assessed for probiotic potential in vitro, including gastrointestinal tolerance, bile salt hydrolase activity, cholesterol-lowering capacity, and fatty acid absorption. Male C57BL/6J mice were fed either a standard chow diet or an HFD for 16 weeks, with HFD mice receiving oral LA-1 supplementation (2 × 10 CFU/day). Multi-omics analyses, including 16S rRNA gene sequencing, short-chain fatty acid (SCFA) quantification, and untargeted liver metabolomics, were employed to investigate the effects of LA-1 on gut microbiota composition, metabolic pathways, and obesity-related phenotypes. : LA-1 supplementation significantly alleviated HFD-induced weight gain, hepatic lipid accumulation, and adipose tissue hypertrophy, without affecting food intake. It improved serum lipid profiles, reduced liver injury markers, and partially restored gut microbiota composition, decreasing the Firmicutes/Bacteroidetes ratio and enriching SCFA-producing genera. Total SCFA levels, particularly acetate, propionate, and butyrate, increased following LA-1 treatment. Liver metabolomics revealed that LA-1 modulated pathways involved in lipid and amino acid metabolism, resulting in decreased levels of acetyl-CoA, triglycerides, and bile acids. : LA-1 exerts anti-obesity effects via gut microbiota modulation, enhanced SCFA production, and hepatic metabolic reprogramming. These findings highlight its potential as a targeted probiotic intervention for obesity and metabolic disorders.
肥胖因其与代谢紊乱和肠道微生物群失调的关联，日益被视为全球健康问题。虽然益生菌有望调节肠道微生物群并改善宿主代谢，但菌株特异性效应仍未得到充分探索，尤其是对于犬源益生菌。本研究旨在分离并鉴定一种新型益生菌菌株LA-1，并使用高脂饮食（HFD）诱导的肥胖小鼠模型评估其抗肥胖作用及潜在机制。LA-1从一只健康犬的粪便中分离出来，并在体外评估其益生菌潜力，包括胃肠道耐受性、胆盐水解酶活性、降胆固醇能力和脂肪酸吸收。雄性C57BL/6J小鼠喂食标准饲料或HFD 16周，HFD组小鼠接受口服LA-1补充剂（2×10CFU/天）。采用多组学分析，包括16S rRNA基因测序、短链脂肪酸（SCFA）定量和非靶向肝脏代谢组学，以研究LA-1对肠道微生物群组成、代谢途径和肥胖相关表型的影响。补充LA-1显著减轻了HFD诱导的体重增加、肝脏脂质积累和脂肪组织肥大，而不影响食物摄入量。它改善了血脂谱，降低了肝脏损伤标志物，并部分恢复了肠道微生物群组成，降低了厚壁菌门/拟杆菌门的比例并富集了产生SCFA的属。LA-1处理后，总SCFA水平，尤其是乙酸盐、丙酸盐和丁酸盐水平升高。肝脏代谢组学显示，LA-1调节了参与脂质和氨基酸代谢的途径，导致乙酰辅酶A、甘油三酯和胆汁酸水平降低。LA-1通过调节肠道微生物群、增强SCFA产生和肝脏代谢重编程发挥抗肥胖作用。这些发现凸显了其作为肥胖和代谢紊乱靶向益生菌干预措施的潜力。
